Ivan Calderon, MD
Family Medicine · Louisville, KYNPI 1043453749
Payments from drug & device makers
Across 427 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$993
- Pfizer$719
- Novo Nordisk$717
- Lilly USA, LLC$603
- GSK$567
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,427100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $1,060 |
| AstraZeneca | 17 | $993 |
| Pfizer | 48 | $719 |
| Novo Nordisk | 49 | $717 |
| Lilly USA, LLC | 45 | $603 |
| GSK | 32 | $567 |
| Boehringer Ingelheim | 23 | $326 |
| Amarin Pharma, Inc. | 14 | $301 |
| Amgen | 20 | $281 |
| Bayer | 14 | $213 |
| Phathom Pharmaceuticals, Inc. | 5 | $184 |
| Exact Sciences | 9 | $140 |
| Gilead | 2 | $137 |
| Esperion Therapeutics, Inc. | 13 | $133 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $104 |
| Johnson & Johnson(2 entities) | 6 | $103 |
| Abbott | 7 | $102 |
| Dynavax Technologies Corporation | 6 | $101 |
| Abiomed | 4 | $98 |
| Novartis | 7 | $95 |
| Biohaven Pharmaceuticals, Inc. | 5 | $84 |
| Astellas Pharma US Inc | 4 | $81 |
| Merck | 4 | $70 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Boston Scientific | 2 | $29 |
| Si-bone, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Globus Medical | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Inogen, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,427 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 125 | $120,651 |
| JardianceEmpagliflozin | 73 | $110,087 |
| FarxigaDapagliflozin Propanediol | 83 | $94,777 |
| OzempicSemaglutide | 66 | $85,007 |
| RybelsusSemaglutide | 27 | $45,935 |
| JanuviaSitagliptin Phosphate | 26 | $36,962 |
| TrulicityDulaglutide | 13 | $23,820 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $22,142 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $20,806 |
| MounjaroTirzepatide | 18 | $20,767 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $12,099 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $11,022 |
| VascepaIcosapent Ethyl | 16 | $10,435 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $6,930 |
| TrulancePlecanatide | 11 | $6,828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $717 | $130,94293 claims |
| PfizerEliquis | $719 | $120,651125 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $326 | $117,01887 claims |
| AstraZenecaFarxiga, Symbicort | $993 | $100,897104 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $603 | $44,58731 claims |
| MerckJanuvia | $70 | $36,96226 claims |
| GSKTrelegy Ellipta | $567 | $20,80623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Louisville
- Christopher RhyneLouisville$1M
- Michael LovelaceLouisville$244K
- Suraj GathaniLouisville$69K
- Mandy WhittLouisville$38K
- Michael PendletonLouisville$29K
- Rajanbhai AminLouisville$26K
- James WrightLouisville$18K
- Rosenberg ReyesLouisville$18K
- Dennis GrayLouisville$14K
- Vincent LangLouisville$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.